CRIS Against Cancer Develops a Blood Test to Predict the Risk of Relapse Into Multiple Myeloma
6 Articles
6 Articles
A team of researchers from the CRIS Unit of Hematological Tumors of the University Hospital 12 de Octubre de Madrid and CRIS Against Cancer has developed a blood test capable of predicting the risk of relapse in patients with multiple myeloma. The work, published in the specialized magazine HemaSphere and coordinated by the ... Continue reading "CRIS Against Cancer develops a blood test to predict the risk of relapse in multiple myeloma"
elcorreogallego.es
A study promoted by the CRIS Anti-Cancer Foundation opens a new way to improve the follow-up of patients with multiple myeloma - a blood cancer that affects the plasma cells of the bone marrow, usually responsible for producing antibodies against infections - by simple blood extraction. The research, led by researchers from the CRIS Hematological Tumors Unit at the University Hospital October 12, Madrid, shows that screening for tumor DNA in the…
The study led by researchers from the CRIS Unit of Hematological Tumors at the University Hospital 12 de Octubre, Madrid, shows that detecting tumor DNA in blood allows identifying patients who have the highest risk of relapse The entry The CRIS Unit of Hematology of CRIS Against Cancer develops a blood test to predict the risk of relapse in patients with multiple myeloma was first published in Correspondents.
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
